Search Results

You are looking at 61 - 70 of 290 items for :

  • "neutropenia" x
Clear All
Full access

Samuel L. Aitken, Jerod L. Nagel, Lilian Abbo, William Alegria, Jason N. Barreto, Sanjeet Dadwal, Alison G. Freifeld, Rupali Jain, Steven A. Pergam, Frank P. Tverdek, Susan K. Seo and on behalf of the Antimicrobial Stewardship in Cancer Consortium ASCC

-specific, evidence-based guidelines and clinical pathways to standardize prescribing is not only feasible but necessary. Examples of highly used pathways in patients with cancer include the management of fever and neutropenia, antifungal prophylaxis and treatment

Full access

Maxim Norkin and John R. Wingard

Because of prolonged neutropenia and severe immunosuppression, patients with hematologic malignancies (HMs) and hematopoietic stem cell transplant (HSCT) recipients are at high risk for invasive fungal infections (IFIs), which are associated with

Full access

Andrew D. Zelenetz and Pamela S. Becker

indications as filgrastim: to treat patients with nonmyeloid malignancies receiving myelosuppressive chemotherapy associated with a clinically significant incidence of febrile neutropenia (FN); patients with acute myeloid leukemia receiving induction or

Full access

Dwight H. Owen, Lai Wei, Ashima Goyal, Ye Zhou, Sheryl-Ann Suffren, Rajani Jacob, Carly Pilcher, Gregory A. Otterson, Claire F. Verschraegen, Manisha H. Shah and Bhavana Konda

-free survival and overall survival data are not mature. Serious adverse events occurred in 4 patients - one patient had grade 3 bronchopulmonary hemorrhage, 3 patients had grade 4 neutropenia and/or thrombocytopenia. There were no treatment-related deaths

Full access

Ju Wang, Ye Zhang, Long Yuan, Lin Ren, Yi Zhang and Xiaowei Qi

any grade (OR=0.37, 95% CrI=0.02-6.81). In addition, Olaparib also showed a low risk of neutropenia for adverse events of 3-4 grade (OR=0.57, 95% CrI=0.06-5.75) compared with Talazoparib. Both Talazoparib and Olaparib were not associated with high risk

Full access

Ramon Mohanlal and Lan Huang

-106 (NCT03294577) with the small molecule immune modulator Plinabulin (Plin) for the prevention of chemotherapy-induced neutropenia (CIN), we unexpectedly observed an increase in plasma Hp levels with Plin. The positive CIN data this trial was reported

Full access

Bradford R. Hirsch and Gary H. Lyman

recombinant human G-CSF made by a subsidiary of Teva Pharmaceuticals that has been approved by the FDA, because the agent has been shown to reduce the duration of severe neutropenia in patients with nonmyeloid malignancies undergoing cancer chemotherapy

Full access

Michael Kleinberg

– 452 . 15 Pizzo PA Hathorn JW Hiemenz J . A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia . N Engl J Med 1986 ; 315 : 552 – 558 . 16 Winston DJ

Full access

Apostolia M. Tsimberidou, Alexandra M. Adamopoulos, Yang Ye, Sarina Piha-Paul, Filip Janku, Siqing Fu, David Hong, Gerald S. Falchook, Aung Naing, Jennifer Wheler, Adoneca Fortier, Razelle Kurzrock and Kenneth R. Hess

regimens; (4) any other grade 3 nonhematologic toxicity, including symptoms/signs of vascular leak or cytokine release syndrome but excluding alopecia; (5) grade 4 thrombocytopenia; (6) any grade 4 neutropenia lasting more than 7 days (as defined by the NCI

Full access

Peter L. Greenberg, Leon E. Cosler, Salvatore A. Ferro and Gary H. Lyman

descriptive review . Nat Clin Pract Oncol 2007 ; 4 : 643 – 656 . 29. Kuderer NM Dale DC Crawford J . Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients . Cancer 2006 ; 106 : 2258 – 2266 . 30